Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 11, 2011 - Issue 3
Submit an article Journal homepage
52
Views
3
CrossRef citations to date
0
Altmetric
Review

Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin’s lymphoma

Ahmad S Halwani Department of Medicine, University of Iowa College of Medicine, Holden Comprehensive Cancer Center, 200 Hawkins Drive, Iowa City, IA 52242, USA; Department of Medicine, University of Iowa College of Medicine, Holden Comprehensive Cancer Center, 200 Hawkins Drive, Iowa City, IA 52242, USA
&
Brian K Link Department of Medicine, University of Iowa College of Medicine, Holden Comprehensive Cancer Center, 200 Hawkins Drive, Iowa City, IA 52242, USA;[email protected]
Pages 443-455 | Published online: 10 Jan 2014

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Randeep Sangha, Andrew Davies, Nam H. Dang, Michinori Ogura, David A. MacDonald, Revathi Ananthakrishnan, M. Luisa Paccagnella, Erik Vandendries, Joseph Boni & Yeow Tee Goh. (2017) Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. Journal of Drug Assessment 6:1, pages 10-17.
Read now

Articles from other publishers (2)

Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan, Taro Ishibashi, M. Luisa Paccagnella, Joseph Boni, Erik Vandendries & David MacDonald. (2016) Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research 22:19, pages 4807-4816.
Crossref
Andre Goy, Andres Forero, Nina Wagner-Johnston, W. Christopher Ehmann, Michaela Tsai, Kiyohiko Hatake, Revathi Ananthakrishnan, Angela Volkert, Erik Vandendries & Michinori Ogura. (2016) A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British Journal of Haematology 174:4, pages 571-581.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.